You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


Advertisement

ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | RSS | Access Rights | Sign In


  Vol. 148 No. 12, December 1988 TABLE OF CONTENTS
  Online Only
 •  Online First Table of
Contents
  ORIGINAL INVESTIGATIONS
 •Online Features
 This Article
 •References
 •Full text PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on Web of Science (25)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Delicious Add to Digg Add to Facebook Add to Reddit Add to Technorati Add to Twitter What's this?

The Use of Theophylline in 'Irreversible' Chronic Obstructive Pulmonary Disease

An Update

Nicholas S. Hill, MD

Arch Intern Med. 1988;148(12):2579-2584.


Abstract



• The use of theophylline in patients with "irreversible" chronic obstructive pulmonary disease is controversial. Possible favorable actions of theophylline, including improved mucociliary clearance, stimulation of respiratory drive, enhanced cardiovascular function, and increased diaphragmatic contractility and endurance, have either been shown to be minor in degree, or have not been demonstrated in patients with irreversible chronic obstructive pulmonary disease. No well-designed trial has yet shown improved exercise capacity following theophylline treatment in these patients. Nevertheless, considering that some patients benefit symptomatically in the absence of objective improvement, a cautious trial of theophylline appears indicated in patients with severe irreversible chronic obstructive pulmonary disease, with discontinuation if there is no objective or subjective improvement. Theophylline therapy should be initiated via the intravenous route during acute exacerbations, but otherwise should start with sustained-release oral preparations of anhydrous theophylline. Oral therapy should begin at low doses in stable patients to avoid side effects, and dosing should take into account the many factors, such as age, cardiovascular and liver function, smoking status, and possible drug interactions, that can affect theophylline metabolism.

(Arch Intern Med 1988;148:2579-2584)



Author Affiliations



From the Division of Pulmonary and Critical Care Medicine, Rhode Island Hospital and Brown University, Providence, RI.


Footnotes



Accepted for publication June 14, 1988.

Reprint requests to Division of Pulmonary and Critical Care Medicine, Rhode Island Hospital, Providence, RI 02903 (Dr Hill).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Delicious Delicious   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

The Clinical Im p lication of Theophylline Intoxication in the Emergency Department
Tsai et al.
Hum Exp Toxicol 1994;13:651-657.
ABSTRACT  

Treatment of Acute Exacerbations of Chronic Obstructive Pulmonary Disease
Rexing et al.
Journal of Pharmacy Practice 1992;5:217-223.
ABSTRACT  

Aminophylline Therapy for Acute Bronchospastic Disease in the Emergency Room
Wrenn et al.
ANN INTERN MED 1991;115:241-247.
ABSTRACT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | PHYSICIAN JOBS | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1988 American Medical Association. All Rights Reserved.